Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707321 | 0.88 | ALDH1A1 (0.41) | ESR1LTA4HPDK2DRD2DRD4 | |
| SCHEMBL5584056 | 0.74 | TYR (0.55) | — | |
| SCHEMBL6438736 | 0.73 | FFAR1 (0.51) | ESR1 | |
| SCHEMBL23082279 | 0.72 | DRD4 (0.43) | CYP19A1ESR1ESR2LTA4HDRD2 | |
| SCHEMBL50738 | 0.70 | TYR (0.54) | — | |
| SCHEMBL8766239 | 0.70 | LTA4H (0.59) | CYP19A1ESR1ESR2LTA4HDRD2 | |
| SCHEMBL1320595 | 0.70 | TAAR1 (0.77) | TAAR1LTA4HPLA2G2A | |
| SCHEMBL5677734 | 0.69 | LMNA (0.51) | ESR1 | |
| SCHEMBL9059711 | 0.69 | PTPN11 (0.47) | — | |
| SCHEMBL23082199 | 0.69 | MMP3 (0.42) | CYP19A1ESR1ESR2LTA4HDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996627-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | PROLIGO L L C (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6262251-B1 | PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS | PROLIGO LLC | 2001-07-17 | — | — | US | disclosed |
| EP-0979233-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO L L C (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0996627-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | Proligo L.L.C. (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0979233-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| US-6001966-A | REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP | PROLIGO LLC (US) | 1999-12-14 | — | — | US | disclosed |
| US-5874532-A | USING A N-TERMINAL PROTECTED AMINO ACID MONOMER | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998047910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0863910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998030578-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1997014706-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-04-24 | — | — | WO | disclosed |